WARNING: DISTANT SPREAD OF TOXIN EFFECT  The effects of DAXXIFY® and all botulinum toxin products may spread from
          the area of injection to produce symptoms consistent with botulinum toxin
          effects. These symptoms have been reported hours to weeks after injection.
          Swallowing and breathing difficulties can be life threatening and there
          have been reports of death. DAXXIFY® is not approved for the treatment
          of spasticity or any conditions other than cervical dystonia and glabellar
          lines. Expand to read more 
 WARNING: DISTANT SPREAD OF TOXIN EFFECT  Expand to read more 
  WARNING: DISTANT SPREAD OF TOXIN EFFECT  
 INDICATION 
 IMPORTANT SAFETY INFORMATION 
 Contraindications 
 Warnings and Precautions 
 The potency Units of DAXXIFY® are not interchangeable with other
    preparations of other botulinum toxin products. Recommended dose and
    frequency of administration should not be exceeded. Patients should seek
    immediate medical attention if respiratory, speech or swallowing
    difficulties occur. Use caution when administering to patients with
    pre-existing cardiovascular disease. Concomitant neuromuscular disorders may
    exacerbate clinical effects of treatment.
 Adverse Reactions 
 Drug Interactions 
 Use in Specific Populations 
 Please see DAXXIFY® full Prescribing Information , including Boxed Warning and Medication Guide .
 DAXI-001720.2
 REFERENCES  Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2022.  Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for
        Injection has a prolonged duration of response in the treatment of
        glabellar lines: pooled data from two multicenter, randomized,
        double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA
        2). J Am Acad Dermatol. 2020;82(4):838-845.
        doi:10.1016/j.jaad.2019.06.1313.  Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc, 2023.  BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2023.  XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2021.  DYSPORT®. Prescribing Information. Ipsen Biopharmaceuticals, Inc.;
        2023.  JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.  DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2022.  Data on File. The Harris Poll Facial Injectables Landmark Survey
        Results. Newark, CA: Revance Therapeutics, Inc, 2018.  Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for
        Injection for the treatment of glabellar lines: results from each of two
        multicenter, randomized, double-blind, placebo-controlled, phase 3
        studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.  Pulkoski-Gross MJ, Fang C, Shai R, Too P. A cell-penetrating peptide
        binds directly to and enhances membrane binding of the core toxin of
        botulinum toxin type A (BoNTA). Poster presented at: TOXINS 2022; July
        27-30, 2022; New Orleans, LA.  Solish N, Carruthers J, Kaufman J, Rubio R, Gross T, Gallagher C.
        Overview of DaxibotulinumtoxinA for Injection: a novel formulation of
        botulinum toxin type A. Drugs. 2021;81:2091-2101.  Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection
        for the treatment of glabellar lines: efficacy results from SAKURA 3, a
        large, open-label, phase 3 safety study. Dermatol Surg.
        2020;47(1):48-54. doi:10.1097/DSS.0000000000002531t.  Green JB, Mariwalla K, Coleman K, et al. A large, open-label, phase 3
        safety study of daxibotulinumtoxinA for injection in glabellar lines: a
        focus on safety from the SAKURA 3 study. Dermatol Surg.
        2021;47(1):42-46. doi:10.1097/DSS.0000000000002463.  Brown J, Stephenson J, Kooken K, Sparrow J. Impact of
        DaxibotulinumtoxinA for Injection on skin smoothness following treatment
        of glabellar lines. Poster presented at: Derm2023 NP/PA CME Conference;
        August 3-6, 2023; Las Vegas, NV.  Data on File. Gross. American Academy of Dermatology. Newark, CA:
        Revance Therapeutics, Inc, 2021.  Data on File. Sak_1_and_Sak_2_facial paresis-asymmetry. Newark, CA:
        Revance Therapeutics, Inc, 2018.  Data on File. D220801002. Newark, CA: Revance Therapeutics, Inc, 2021.